Novel therapeutic strategies in ALL 

Jae Park, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses novel therapeutic strategies for managing acute lymphoblastic leukemia (ALL). He highlights advancements in immunotherapy, including CAR T-cells, which have proven effective in relapsed/refractory (R/R) cases and are now being explored for earlier treatment stages and T-cell ALL. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.